Associated tags: Female, Medicines and Healthcare products Regulatory Agency, FDA, Food, RWS, EC, USPI, Uterine fibroid, European, MHRA, Pregnancy, New Drug Application, Sumitomo Pharma, Woman, Safety, Pain, Endometriosis, Infertility, Pharmaceutical industry, Birth control, NYSE, Roivant Sciences, Regulation of food and dietary supplements by the U.S. Food and Drug Administration
Locations: LIECHTENSTEIN, AFRICA, NORWAY, EUROPEAN UNION, TURKEY, INDIA, UNITED KINGDOM, MIDDLE EAST, ICELAND, ASIAN, CANADA, LONDON, NEW YORK CITY, SAN FRANCISCO, CALIFORNIA, NEW YORK, NY, FLORIDA, HAWAII
Retrieved on:
Thursday, January 26, 2023
Research,
Prostate cancer,
Food,
Gonadotropin-releasing hormone,
USPI,
Scott Richter,
Endometriosis,
Hart–Scott–Rodino Antitrust Improvements Act,
History,
Sale,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
FDA,
SG,
Roivant Sciences,
SPIRIT,
ORGOVYX,
New Drug Application,
EMA,
Woman,
RWS,
Shanda,
United Kingdom,
Type 2,
TRX,
Richter,
Pain,
Safety,
PDUFA,
R,
NYSE,
Type,
Risk,
European Medicines Agency,
Calendar,
Patient,
Growth,
Uterine fibroid,
German–Soviet Commercial Agreement (1940),
Leuprorelin,
Video game,
Fine chemical,
Credit,
Security (finance),
Pharmaceutical industry,
Health insurance,
Medical imaging,
Airline,
Takeda,
Accord,
Pfizer Third fiscal quarter 2022 net product revenues for ORGOVYX in the U.S. were $48.7 million, reflecting 12% sequential growth compared to the second fiscal quarter 2022.
Key Points:
- Third fiscal quarter 2022 net product revenues for ORGOVYX in the U.S. were $48.7 million, reflecting 12% sequential growth compared to the second fiscal quarter 2022.
- Approximately 4,000 new patients started treatment with ORGOVYX in the third fiscal quarter of 2022, reaching approximately 26,000 cumulative patients since launch.
- In December 2022, Myovant completed a New Drug Submission to Health Canada seeking marketing approval for ORGOVYX for advanced prostate cancer.
- Third fiscal quarter 2022 net product revenues for MYFEMBREE in the U.S. were $10.5 million, reflecting 64% sequential growth compared to second fiscal quarter 2022.
Retrieved on:
Wednesday, November 16, 2022
The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.
Key Points:
- The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.
- The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 149,300 common shares ofMyovant.
- The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable RSU agreements.
- Myovant Sciencesaspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy worldwide.
Retrieved on:
Wednesday, November 16, 2022
Loyola University Chicago,
Roivant Sciences,
Culture,
Head,
Science,
History,
University,
AbbVie,
Abbott Laboratories,
Executive Committee,
S-1 Executive Committee,
Senior,
Abbott,
Loyola University,
NYSE,
Human resources,
Woman,
HR,
Pharmacyclics,
Management BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources.
Key Points:
- BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources.
- Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovants global functions.
- "We are delighted to welcome Ann to Myovant during this exciting time of the companys growth," said David Marek, Chief Executive Officer of Myovant Sciences, Inc.
- "I am thrilled to join Myovant at this pivotal time for the company," said Ms. Tomlin, Senior Vice President for Human Resources of Myovant Sciences, Inc. "Myovant has proven to be an industry leader through its science, successful product launches and commitment to patient-centered transformative advocacy.
Retrieved on:
Wednesday, October 26, 2022
Second fiscal quarter 2022 net product revenues for ORGOVYX in the U.S. were $43.3 million, reflecting 20% sequential growth compared to the first fiscal quarter 2022.
Key Points:
- Second fiscal quarter 2022 net product revenues for ORGOVYX in the U.S. were $43.3 million, reflecting 20% sequential growth compared to the first fiscal quarter 2022.
- Approximately 4,000 new patients started treatment with ORGOVYX in the second fiscal quarter of 2022, reaching approximately 22,000 cumulative patients since launch.
- Second fiscal quarter 2022 net product revenues for MYFEMBREE in the U.S. were $6.4 million, reflecting 60% sequential growth compared to first fiscal quarter 2022.
- Approximately 3,200 new patients started treatment with MYFEMBREE in the second fiscal quarter 2022, resulting in 55% sequential quarterly growth in the number of patients treated since launch.
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (Myovant) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time.
Key Points:
- BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (Myovant) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time.
- The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd.
Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy worldwide.
- Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across hormone-sensitive oncology and womens health leading to five regulatory approvals in the United States and Europe.
- Myovant and its partners continue to file for additional indications of its lead products as well as continue further development of pipeline assets.
Slate,
Skadden,
Reading,
CEO,
Pediatrics,
LLP,
Communication,
Roivant Sciences,
THE,
NYSE,
AND,
Report of the Special Committee on the Termination of the National Emergency,
Company,
Committee,
GLOBE,
FDA,
Risk,
New,
Growth,
Woman,
Hand,
Â,
Special,
Oliver Cromwell,
Board,
Prostate cancer,
Goldman Sachs,
Schedule,
Sullivan & Cromwell,
U.S. Securities and Exchange Commission,
SEC,
Schedule 13D,
Sumitomo Mitsui Banking Corporation,
Patient,
Biotechnology,
Man,
Urology,
Acquisition,
Health,
Form,
Forward-looking statement,
COVID-19,
Security (finance),
Fine chemical,
Risk management,
Pharmaceutical industry,
Management NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”), and Myovant Sciences (“Myovant”) (NYSE: MYOV) announced today that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis, and a total company value of $2.9 billion on a fully diluted basis. Sumitovant currently beneficially owns 52% of the issued and outstanding shares of Myovant as more particularly described in Sumitovant’s Schedule 13D/A filed with the U.S. Securities and Exchange Commission (the “SEC”).
Key Points:
- NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) (NYSE: MYOV) announced today that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.
- We are pleased to have reached an agreement with Sumitovant and Sumitomo Pharma that recognizes the remarkable success Myovant has achieved, said David Marek, CEO of Myovant.
- This communication contains forward-looking statements, including statements regarding expectations about the proposed transaction involving Myovant, Sumitovant and Sumitomo Pharma.
- Myovant, Sumitovant and Sumitomo Pharma disclaim any obligation to update these forward-looking statements, except as may be required.
Slate,
Skadden,
Reading,
CEO,
Pediatrics,
ORGOVYX,
Communication,
Roivant Sciences,
THE,
NYSE,
AND,
Report of the Special Committee on the Termination of the National Emergency,
Company,
Committee,
FDA,
Risk,
New,
Growth,
Woman,
Hand,
Annual general meeting,
Oliver Cromwell,
Board,
Prostate cancer,
Goldman Sachs,
Schedule,
Sullivan & Cromwell,
U.S. Securities and Exchange Commission,
SEC,
Schedule 13D,
Sumitomo Mitsui Banking Corporation,
Patient,
Biotechnology,
Man,
Urology,
Acquisition,
Health,
Form,
Forward-looking statement,
COVID-19,
Security (finance),
Fine chemical,
Pharmaceutical industry,
Management NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ -- Sumitovant Biopharma Ltd. ("Sumitovant"), in conjunction with parent company Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), and Myovant Sciences ("Myovant") (NYSE: MYOV) announced today that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis, and a total company value of $2.9 billion on a fully diluted basis. Sumitovant currently beneficially owns 52% of the issued and outstanding shares of Myovant as more particularly described in Sumitovant's Schedule 13D/A filed with the U.S. Securities and Exchange Commission (the "SEC").
Key Points:
- NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ -- Sumitovant Biopharma Ltd. ("Sumitovant"), in conjunction with parent company Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), and Myovant Sciences ("Myovant") (NYSE: MYOV) announced today that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.
- "We are pleased to have reached an agreement with Sumitovant and Sumitomo Pharma that recognizes the remarkable success Myovant has achieved," said David Marek, CEO of Myovant.
- This communication contains forward-looking statements, including statements regarding expectations about the proposed transaction involving Myovant, Sumitovant and Sumitomo Pharma.
- Myovant, Sumitovant and Sumitomo Pharma disclaim any obligation to update these forward-looking statements, except as may be required.
Retrieved on:
Tuesday, October 18, 2022
LinkedIn,
RSU,
Female,
MHRA,
Review,
Woman,
New Drug Application,
Employment,
NYSE,
Twitter,
Man,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Food,
Medicines and Healthcare products Regulatory Agency,
Pain,
Safety,
USPI,
GLOBE,
EC,
RWS,
Infertility,
Uterine fibroid,
FDA,
Pregnancy,
Endometriosis,
Pharmaceutical industry The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.
Key Points:
- The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.
- The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 96,500 common shares ofMyovant.
- The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable RSU agreements.
- Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.
Promoting Resilience and Efficiency in Preparing for Attacks and Responding to Emergencies (PREPARE) Act of 2017,
Fund,
First responder,
Foundation,
Firefighter,
Tropical Storm Ian,
Partnership,
Emergency Disaster Loan Program,
Emergency medical technician,
CEO,
GLOBE,
Disaster recovery,
Nursing,
Tropical cyclone,
Community engagement,
Bottled water,
Public relations,
Medicine We are grateful for the Emergency Disaster Grants that First Responders Children's Foundation and SERVPRO are providing to our first responders."
Key Points:
- We are grateful for the Emergency Disaster Grants that First Responders Children's Foundation and SERVPRO are providing to our first responders."
- The First Responders Childrens Foundation Hurricane Ian Disaster Response Fundis made possible by SERVPROs corporate office and the Foundation is appealing to more corporate partners and individual donors to support the Fund.
- First Responders Childrens Foundation is ready to step in when first responders and their families need us most, said Jillian Crane, First Responders Childrens Foundation President and CEO.
- Contributions to the The First Responders Childrens Foundation Hurricane Ian Disaster Response Fund can be made by visiting: www.1stRCF.org/ian or by contacting Randy Acosta at [email protected].
LinkedIn,
Medicines and Healthcare products Regulatory Agency,
Female,
Webcast,
MHRA,
Royal commission,
Woman,
Review,
New Drug Application,
Roivant Sciences,
NYSE,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Twitter,
Man,
Food,
Pain,
Safety,
USPI,
GLOBE,
EC,
RWS,
Infertility,
Uterine fibroid,
FDA,
Pregnancy,
Endometriosis,
European Commission,
Pharmaceutical industry BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022.
Key Points:
- BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022.
- The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022.
- Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.
- Myovant also is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis.
